机构：[a]Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, People’s Republic of China神经科系统神经内科首都医科大学宣武医院[b]National Clinical Research Center for Geriatric Diseases, Beijing, People’s Republic of China[c]Clinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing, People’s Republic of China[d]Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, People’s Republic of China
Alzheimer's disease (AD) research is entering a unique moment in which enormous information about the molecular basis of this disease is being translated into therapeutics. However, almost all drug candidates have failed in clinical trials over the past 30 years. These many trial failures have highlighted a need for the incorporation of biomarkers in clinical trials to help improve the trial design. Fluid biomarkers measured in cerebrospinal fluid and circulating blood, which can reflect the pathophysiological process in the brain, are becoming increasingly important in AD clinical trials. In this review, we first succinctly outline a panel of fluid biomarkers for neuropathological changes in AD. Then, we provide a comprehensive overview of current and future application of fluid biomarkers in clinical trials for AD. We also summarize the many challenges that have been encountered in efforts to integrate fluid biomarkers in clinical trials, and the barriers that have begun to be overcome. Ongoing research efforts in the field of fluid biomarkers will be critical to make significant progress in ultimately unveiling disease-modifying therapies in AD.
基金：
Key Project of 594
the National Natural Science Foundation of China 595
(81530036); the National Key Scientific Instrument 596
and Equipment Development Project (31627803); 597
Mission Program of Beijing Municipal Admin- 598
istration of Hospitals (SML20150801); Beijing 599
Scholars Program; Beijing Brain Initiative from 600
Beijing Municipal Science & Technology Commis- 601
sion (Z161100000216137); Project for Outstand- 602
ing Doctor with Combined Ability of Western 603
and Chinese Medicine; and Beijing Municipal 604
Commission of Health and Family Planning(PXM2 605
019 026283 000003).
第一作者机构：[a]Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, People’s Republic of China
通讯作者：
通讯机构：[*1]Innovation Center for Neurological Disorders, Department of Neurology, Xuanwu Hospital, Capital Medical University, 45 Changchun Street, Beijing, China.
推荐引用方式(GB/T 7714)：
Yang Jianwei,Jia Longfei,Li Yan,et al.Fluid Biomarkers in Clinical Trials for Alzheimer's Disease: Current and Future Application.[J].JOURNAL OF ALZHEIMERS DISEASE.2021,81(1):19-32.doi:10.3233/JAD-201068.
APA：
Yang Jianwei,Jia Longfei,Li Yan,Qiu Qiongqiong,Quan Meina&Jia Jianping.(2021).Fluid Biomarkers in Clinical Trials for Alzheimer's Disease: Current and Future Application..JOURNAL OF ALZHEIMERS DISEASE,81,(1)
MLA：
Yang Jianwei,et al."Fluid Biomarkers in Clinical Trials for Alzheimer's Disease: Current and Future Application.".JOURNAL OF ALZHEIMERS DISEASE 81..1(2021):19-32
